Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.

Hervé Avet-Loiseau,Jesús F. San Miguel,Tineke Casneuf,Shinsuke Iida,Sagar Lonial,Saad Z. Usmani,Andrew Spencer,Philippe Moreau,Torben Plesner,Katja Weisel,Jon Ukropec,Christopher Chiu,Sonali Trivedi,Himal Amin,Maria Krevvata,Priya Ramaswami,Xiang Qin,Mia Qi,Steven Sun,Ming Qi,Rachel Kobos,Nizar J. Bahlis

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.

2021

PURPOSEIn relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumuma...

Keywords:

Lenalidomide
Minimal Residual Disease Negativity
Gastroenterology
Internal medicine
Minimal residual disease
Bortezomib
Refractory Multiple Myeloma
Dexamethasone
Population
Medicine
Daratumumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations